BioSpace News Archive

Clinical trial news definitely picked up this final week of January. Here’s a look.

TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.

Leading China -based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC).

The HIV/AIDS monitoring test deals with post-HIV detection to assess plasma status and immune function of HIV-infected patients.

Neuralgia refers to an abnormal symptom that comes with several effects, such as severe, burning, and sharp pain owing to the presence of a damaged or an irritated nerve.

The global point of care CT imaging market is foreseen to register promising growth trajectory during 2019–2029.

The protein therapeutics market has been anticipated to experience various growth opportunities in the years to come.

The organic order intake increased 6.4% in the fourth quarter following growth in all business areas and regions

Calliditas Therapeutics AB announced the commercial availability and initial sales of TARPEYO™, the first and only FDA approved treatment for IgA nephropathy, indicated for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio ≥1.5g/g.

BeiGene announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and granted BRUKINSA breakthrough therapy designation.